Investors can contact the law firm at no cost to learn more about recovering their losses

LOS ANGELES, July 22, 2025 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Organon & Co. ("Organon" or the "Company") (NYSE: OGN) investors of a class action representing investors that bought securities between November 3, 2022 and April 30, 2025, inclusive (the "Class Period"). Organon investors have until July 22, 2025to file a lead plaintiff motion.

Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 310-692-8883 or email: lesley@portnoylaw.com, to discuss their legal rights, or click here to join the case. The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors' options for pursuing claims to recover their losses.

CASE ALLEGATIONS: Organon is a healthcare company that develops and delivers prescription therapies and medical devices.

According to the class action lawsuit, throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose material facts, including that:(i) Organon concealed critical information regarding its capital allocation strategy--particularly its plans for the quarterly dividend payout;(ii) despite public statements positioning the dividend as the company's "number one priority," Organon had adopted a debt reduction strategy that conflicted with maintaining the dividend; and(iii) following its acquisition of Dermavant Sciences Ltd., Organon intended to shift capital priorities toward debt reduction, leading to a substantial dividend cut.

The Complaint further alleges that on May 1, 2025, Organon released its Q1 2025 financial results and announced a sharp reduction in its quarterly dividend--from $0.28 to $0.02 per share. On this news, Organon's stock declined more than 27%, according to the Complaint.

Please visit our website to review more information and submit your transaction information.

The Portnoy Law Firm represents investors in pursuing claims against caused by corporate wrongdoing. The Firm's founding partner has recovered over $5.5 billion for aggrieved investors. Attorney advertising. Prior results do not guarantee similar outcomes.

Lesley F. Portnoy, Esq.Admitted CA and NY Barlesley@portnoylaw.com310-692-8883www.portnoylaw.com

Attorney Advertising

COMTEX_467487629/2010/2025-07-22T17:37:33

Investors can contact the law firm at no cost to learn more about recovering their losses

LOS ANGELES, July 22, 2025 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Organon & Co. ("Organon" or the "Company") (NYSE: OGN) investors of a class action representing investors that bought securities between November 3, 2022 and April 30, 2025, inclusive (the "Class Period"). Organon investors have until July 22, 2025to file a lead plaintiff motion.

Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 310-692-8883 or email: lesley@portnoylaw.com, to discuss their legal rights, or click here to join the case. The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors' options for pursuing claims to recover their losses.

CASE ALLEGATIONS: Organon is a healthcare company that develops and delivers prescription therapies and medical devices.

According to the class action lawsuit, throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose material facts, including that:(i) Organon concealed critical information regarding its capital allocation strategy--particularly its plans for the quarterly dividend payout;(ii) despite public statements positioning the dividend as the company's "number one priority," Organon had adopted a debt reduction strategy that conflicted with maintaining the dividend; and(iii) following its acquisition of Dermavant Sciences Ltd., Organon intended to shift capital priorities toward debt reduction, leading to a substantial dividend cut.

The Complaint further alleges that on May 1, 2025, Organon released its Q1 2025 financial results and announced a sharp reduction in its quarterly dividend--from $0.28 to $0.02 per share. On this news, Organon's stock declined more than 27%, according to the Complaint.

Please visit our website to review more information and submit your transaction information.

The Portnoy Law Firm represents investors in pursuing claims against caused by corporate wrongdoing. The Firm's founding partner has recovered over $5.5 billion for aggrieved investors. Attorney advertising. Prior results do not guarantee similar outcomes.

Lesley F. Portnoy, Esq.Admitted CA and NY Barlesley@portnoylaw.com310-692-8883www.portnoylaw.com

Attorney Advertising

COMTEX_467487629/2010/2025-07-22T17:37:33